Factory Top Purity Peptide Kpv Nad+ Mots-C Cagrilintide Tirzepatide Retatrutide Dsip Ss-31 HMG Door-to-Door Service

NAD

Adenosine 5′-(trihydrogen diphosphate),P′→5′-ester with 3-(aminocarbonyl)-1-β-D-ribofuranosylpyridinium,inner salt;Pyridinium,3-carbamoyl-1-β-D-ribofuranosyl-,hydroxide,5′→5′-ester with adenosine 5′-(trihydrogen pyrophosphate),inner salt;Adenosine 5′-(trihydrogen diphosphate),P′→5′-ester with 3-(aminocarbonyl)-1-β-D-ribofuranosylpyridinium hydroxide,inner salt;Codehydrase I;Codehydrogenase I;Coenzyme I;Diphosphopyridine nucleotide;DPN;Cozymase I;NAD;Nadide;Nicotinamide-adenine dinucleotide;Oxidized diphosphopyridine nucleotide;Adenine-nicotinamide dinucleotide;NAD+;Enzopride;β-NAD;β-Diphosphopyridine nucleotide;β-Nicotinamide adenine dinucleotide;β-NAD+;NSC 20272;CO-I;β-Nicotinamide adenine dinucleotide hydrate;30429-30-2;159929-29-0;1083039-67-1;1354693-98-3

53-84-9

C21H27N7O14P2

InChIKey=BAWFJGJZGIEFAR-NNYOXOHSSA-N

663.43

663.109131

200-184-4

757121

DTXSID2045236

C87339

29349990

Other Chemical Drugs

321

-1.29620

White Powder

140-142 °C (decomp)

soluble in water at 50mg/ml

2-8°C

D20 -31.5° (c = 1.2 in water)

226.7 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]|227.5 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|222.7 Ų [M+Na]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|223.8 Ų [M-H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|230.8 Ų [M+Na-2H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|227 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)

Investigational — Phase 3 (REDEFINE program, CagriSema combination)

A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.

Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.

MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.

NCT05249895; NCT05249882

PubChem

MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation

Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.